“Novartis Canada is proud to be one of the first sponsors to partner with CATALIS. Through this partnership, we have successfully conducted a radioligand therapy trial for the PSMA indication. By using the CATALIS FAST TRACK Evaluation Service, we were able to initiate the trial earlier, with the added milestone of the first patient visit in Canada. This achievement underscores the importance of efficiency and effectiveness in clinical trials and demonstrates Quebec’s commitment to accelerate clinical trials. We are confident that this ongoing collaboration will continue to deliver value and further demonstrate our commitment to advancing research that will have a positive impact on patients and their families.”
